• +1 240 760 2512
  • info@kammerman.com

Advancing Endpoint Development for Preterm Neonates with Pulmonary Morbidities

2 October 2018

Washington, DC

Duke-Margolis Center for Health Policy

Invited endpoints expert

From the meeting abstract:

“Under a cooperative agreement with FDA, the Duke-Margolis Center for Health Policy is convening this expert workshop to provide stakeholders the opportunity to explore and discuss the work that has been done to date on efficacy endpoint development for preterm neonates with pulmonary morbidities, highlight gaps and limitations in existing data and research, and identify a path forward to develop validated endpoints and COAs that better represent short- and long-term outcomes associated with pulmonary morbidities of prematurity.”